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Symmetric dimethylarginine (SDMA) indirectly inhibits nitric oxide (NO) synthesis and predicts cardiovascular and all-cause
mortality in high-risk patients. The aim of our study was to investigate the associations of cumulative inflammatory burden
(assessed by serial measurements of inflammatory markers) and classical cardiovascular (CV) disease risk factors with SDMA
in RA patients. 201 RA patients (155 females, median age 67 (59–73)) were assessed at baseline (2006). Classical CV disease risk
factors were recorded and systemic inflammationwas determined by themeasurement of C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR). At follow-up (2012) SDMA levels were measured by enzyme-linked immunosorbent assay. Mean SDMA
levels in RA population were 0.40 (0.40–0.53) 𝜇mol/L. No significant association between SDMA and cumulative inflammatory
load was established in the analysis. SDMA levels were not found to be significantly related to CV disease risk factors. We explored
the potential relationship between SDMA and cumulative inflammatory burden in patients with RA and obtained negative results.
SDMA did not relate to CV disease risk factors in our population and its clinical significance as a surrogate marker of endothelial
dysfunction in patients with RA remains to be determined.
1. Introduction
There is a substantial amount of evidence suggesting that
cardiovascular (CV) disease is the most common cause of
premature mortality in patients with rheumatoid arthritis
(RA) [1]. Even after adjusting for traditional CV risk factors,
themagnitude of CV risk in RA is increased by approximately
50% compared to the general population [2]. Components
of cardiometabolic syndrome such as dyslipidemia, insulin
resistance, and hypertension are more common in patients
with RA leading to endothelial dysfunction and coronary
artery disease [3].
It is well-recognised that the endothelium is the key
regulator of vascular function by controlling vascular tone,
smoothmuscle proliferation, platelet aggregation, andmigra-
tion of adhesion molecules [4]. Inflammation in RA has a
systemic nature and inflammatory molecules and cytokines
exhibit deleterious effects on the vasculature resulting in
endothelial dysfunction. Derangement of endothelial home-
ostasis is an early preclinical marker of atherosclerosis and
several studies have demonstrated that endothelial dysfunc-
tion is more prevalent in RA patients compared to controls
[5]. The damaged endothelium disrupts the metabolism of
nitric oxide (NO) which is the most important vasoactive
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agent for the maintenance of basal vasodilator tone and vas-
cular patency.Therefore, dysregulation of NOproduction has
been considered as the cornerstone of endothelial dysfunc-
tion and much attention has been paid to the identification
of pathways associated with suppression of NO synthase
activity, the enzyme responsible for NO synthesis.
Dimethylarginines are by-products of the posttransla-
tional methylation of arginine residues in proteins and they
interfere with NO formation by inhibiting NO synthase
which, in turn, leads to endothelial dysfunction. Asymmet-
rical dimethylarginine (ADMA) is the most potent inhibitor
of NO synthase and has emerged as a novel biomarker of
CV outcome and mortality among patients with intermittent
and high CV risk, as well as in the general population
[6, 7]. Since the details of the mechanisms accompanying
this effect are unravelling, interest has started to divert
towards symmetrical dimethylarginine (SDMA), the inactive
congener of ADMA which has not been studied to a similar
extent. SDMA ismainly excreted by kidneys andmay provide
amechanistic link between renal dysfunction andCVdisease.
Elevated SDMA levels are associated with adverse outcomes
in stroke [8], worse prognosis in patients referred for coro-
nary angiography [9], and all-cause and CV mortality in the
general population [10].
These findings suggest that SDMAmay have an indepen-
dent role in the pathogenesis of endothelial dysfunction and
CV disease, by inhibiting both renal and cellular uptake of L-
arginine, thus also potentially diminishingNObioavailability
[11, 12]. In addition, SDMA inducesmonocyte-mediated reac-
tive oxygen species production [13] and has been described
as a proinflammatory agent in chronic kidney disease [14].
In RA, the magnitude of the inflammatory response over
time (cumulative inflammatory burden) rather than a single
determination of inflammatorymarkers may bemore impor-
tant for the development and progression of vascular injury
[15]. Despite emerging data in several conditions associated
with atherosclerosis and CV disease, the role of SDMA in
RA remains largely unexplored. The aim of the present study
was to investigatewhether cumulative systemic inflammatory
burden and/or classical CV risk factors in RA associate with
SDMA in a large well-characterized cohort of patients with
long-standing RA.
2. Materials and Methods
2.1. Study Participants. We studied 201 patients with RA.
The patients were part of the Dudley Rheumatoid Arthritis
Comorbidity Cohort (DRACCO), a prospective study exam-
ining CV burden in RA. These individuals have participated
in other studies of cardiovascular risk factors, and patient
characteristics and detailed methods have been previously
described [16, 17]. In summary, 201 out of 400 patients
initially recruited in 2006 performed a follow-up visit in
2012. Seventy-eight patients had died since 2006 and the
remaining 121 declined to participate for personal reasons.
Exclusion criteria for the present study were confirmed acute
coronary syndrome, evidence of chronic kidney disease,
or serious psychiatric disorders according to their medical
records. All patients met the 1987 revised RA criteria of the
American College of Rheumatology [18]. The study received
ethics approval from The Black Country Research Ethics
Committee. All participants gave their written informed
consent according to the Declaration of Helsinki.
2.2. Protocol for Baseline. Patients were evaluated after a 12-
hour overnight fast and underwent a standardised clinical
interview, physical examination, and detailed review of their
medical history and hospital records. Height and weight were
measured and the body mass index (BMI) was calculated
(using a TANITA Body Composition Analyser BC-418).
Disease activity score (DAS28) [19] and physical function
using the Health Assessment Questionnaire (HAQ) [20]
were recorded. Chart review with RA treatment and current
therapy for other indications was performed. A blood sample
was also obtained on the same day for the assessments of
routine hematologic and biochemistry, lipid profile, fasting
glucose, fasting insulin, and acute phase response. Insulin
resistance was determined by using the Homeostasis Model
Assessment Insulin Resistance (HOMA-IR) andQuantitative
Insulin Sensitivity Check Index (QUICKI), as previously
described [21, 22]. All biochemical tests were carried out in
the Biochemistry Laboratory at Russells Hall Hospital, The
Dudley Group NHS Foundation Trust, UK.
2.3. Protocol for Follow-Up Visit. Patients reported to the
same clinical research facility as in the baseline assessment
in 2012 after a 12-hour overnight fast. A venous blood
sample was collected to assess SDMA levels. The SDMA
assay is based on the method of competitive enzyme-linked
immunoassays.The sample preparation includes the addition
of a derivatization-reagent for SDMA coupling. During the
incubation period, the target SDMA in the sample competes
with the SDMA derivative (tracer) immobilised on the wall
of the microtiter plates for the binding of the polyclonal
antibodies.The SDMA in the sample displaces the antibodies
out of the binding to the tracer. Therefore, the concentration
of the tracer-bound antibody is inversely proportional to
the SDMA concentration in the sample. The absorbance is
measured at 450 nm and patient samples are read from a
standard curve.
The intra-assay standard deviation was 7.5% and interas-
say was 6%. The lowest amount detected was 0.05 𝜇mol/L.
2.4. Cumulative Inflammatory Burden. Detailed information
on erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) from the baseline visit to the follow-up visit for
each patient was used to calculate cumulative inflammatory
burden. A quarterly measurement of CRP and ESR for each
year the patient was in the study was used to calculate the
area under the curve (AUC) for each parameter. ESR was
measured using the StaRRsed Auto Compact blood sedi-
mentation instrument (Mechatronics, Zwaag, Netherlands)
and CRP was measured using the VITROS 5,1 FS Chemistry
System (Ortho-Clinical Diagnostics, Rochester, NY, USA).
2.5. Statistical Analysis. Several of the variables being consid-
ered, including SDMA, followed skewed distributions.Where
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Figure 1: Graphic demonstration of the associations between SDMAandAAUCs of CRP (a) and ESR (b). Cumulative inflammation is plotted
on a logarithmic scale, and the fit line and related statistics are based on the regressionmodels in Table 2. SDMA: symmetric dimethylarginine,
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, and AAUC: average area under the curve.
this was the case, log
2
-transformations were applied to the
data prior to the analysis, to allow the use of parametric
tests. AUCs for ESR and CRP data were calculated for the
quarterly measurements made between 2006 and 2012. Since
some patients had missing data at the start or end of the
period, the AUCs were dependent on the length of time the
data were available. For this reason, the resulting AUCs were
divided by the total period that data were available for each
patient to produce average AUCs (AAUCs).
The log
2
-transformed SDMA values were then compared
across categorical factors using independent samples 𝑡-tests
for dichotomous factors and one-way ANOVA where there
were multiple categories. For the continuous factors, regres-
sion models were produced to quantify relationships with
SDMA. All of the factors from the univariable analysis were
then considered for inclusion in a multivariable regression
model, using a forward stepwise entry method, in order to
account for the potential effects of confounding.
All analyses were performed using IBM SPSS Statistics 22
(IBM Corp. Armonk, NY). Missing data was excluded on a
per analysis basis, and 𝑝 < 0.05 was deemed to be indicative
of statistical significance.
3. Results and Discussion
3.1. Results. The characteristics of the participants at baseline
and follow-up as well as the general demographics are
summarised in Table 1. The majority of the patients were
female with relatively low disease activity score and acute
phase response, parameters indicating optimal RA control
despite long disease duration.
Data were available for 201 patients, of whom 197 had
SDMAmeasurements. After being log
2
-transformed, SDMA
was found to closely follow a normal distribution, with the
exception of 11 (6%) patients with SDMA values >1. These
outliers were excluded from the data, in order to make
parametric analysis valid and to prevent them frombecoming
excessively influential in the tests performed.
Univariable analysis of SDMA found only two factors
to be significant predictors, namely, estimated glomerular
filtration rate (eGFR) (𝑝 = 0.024) and creatinine (𝑝 = 0.016)
(Table 2). For eGFR, the relationship was negative, with a one
unit increase associated with a 0.3% (95% CI: 0.0%, 0.5%)
reduction in SDMA. Creatinine, on the other hand, had a
positive relationship with SDMA, with a twofold increase in
the former associated with a 12.0% (95% CI: 2.2%, 22.8%)
increase in the latter. Neither of the cumulative inflammatory
markers was found to be significantly correlated with SDMA,
with 𝑝 = 0.916 for the AAUC of CRP and 𝑝 = 0.192 for the
AAUC of ESR (Table 2). This is demonstrated graphically in
Figure 1.
Univariable analysis of categorical factors found no sig-
nificant associations between SDMA, traditional CV dis-
ease risk factors, and treatment with steroids, methotrexate,
tumour necrosis factor-alpha inhibitors, or antihypertensive
agents (Table 3).
To consider the potential for confounding factors, mul-
tivariable analyses were performed, using forward stepwise
regression models, with all of the variables in Tables 2 and 3
as potential covariates. Creatinine was the only factor entered
into the final model, which was expected, since none of the
other factors were significant in univariable analysis with
the exception of eGFR, which was highly correlated with
creatinine (Pearson’s 𝑟: −0.83, 𝑝 < 0.001).
3.2. Discussion. In this study, we assessed for the first time the
relationship between SDMA and cumulative inflammatory
burden and traditional CV risk factors in RA patients.
Although SDMA has been reported as a surrogate marker
of endothelial dysfunction in a number of conditions char-
acterised by excess CV morbidity, no significant associations
with disease-related inflammation,metabolic factors, andCV
risk scores were detected in our RA population.
RA is characterized by a heightened inflammatory state
and the chronic intense interaction occurring between
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Table 1: Patient characteristics at baseline and at follow-up (SandooA,Dimitroulas T,Hodson J, Smith JP, Douglas KM,Kitas GD. Cumulative
inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology. 2014 Sep 3.
[Ahead of print]. Reproduced with permission from Oxford University Press).
Baseline (2006) Follow-up (2012)
General characteristics
Age (years) 61 (53–67) 67 (59–73)
Sex female𝑁 (%) 155 (77%) 155 (77%)
Body mass index (kg/M2) 27 (24–30) 28 (24–32)
Disease characteristics
Disease duration (years) 10 (4–18) 16 (11–25)
Rheumatoid factor positive𝑁 (%) 148 (74%) 148 (74%)
Anti-CCP positive𝑁 (%) 123 (61%) 123 (61%)
DAS28 4.0 (3.1–4.8) 3.1 (2.5–4.0)
HAQ 1.3 ± 0.9 1.6 ± 0.9
C-reactive protein (mg/L) 7.5 (4.3–16) 3 (2.9–8.5)
Erythrocyte sedimentation rate (mm/hr) 17 (8–30) 12 (5–23)
SDMA (𝜇mol/L) — 0.47 (0.40–0.53)
Cardiovascular disease risk factors
Hypertension𝑁 (%) 132 (66%) 130 (65%)
Dyslipidemia𝑁 (%) 115 (57%) 158 (79%)
Insulin resistance𝑁 (%) 65 (32%) 53 (26%)
Diabetes𝑁 (%) 7 (4%) 21 (10%)
Global CVD risk scores
Framingham Risk Score (%) 4 (1–8) 8 (5–13)
Reynolds Risk Score (%) 6 (3–13) 8 (3–14)
RA Medications
Methotrexate𝑁 (%) 128 (64%) 122 (61%)
Prednisolone𝑁 (%) 58 (29%) 51 (25%)
NSAID’s𝑁 (%) 47 (23%) 26 (13%)
Cyclooxygenase II inhibitors𝑁 (%) 14 (7%) 5 (3%)
Anti-TNF𝛼 therapy𝑁 (%) 20 (10%) 57 (28%)
Tocilizumab𝑁 (%) — 3 (2%)
Cardiovascular medications
Antihypertensive𝑁 (%) 81 (40%) 79 (39%)
Antihypercholesterolemic𝑁 (%) 33 (16%) 74 (37%)
Beta-blocker𝑁 (%) 32 (16%) 22 (11%)
Calcium channel blocker𝑁 (%) 26 (13%) 27 (13%)
Results are expressed asmedian (25th to 75th percentile values), mean± standard deviation or number (percentage). DAS28 = disease activity score in 28 joints.
Anti-TNF𝛼 = antitumour necrosis factor alpha; CCP = citrullinated protein antibody; HAQ =Health Assessment Questionnaire; NSAID’s = nonsteroidal anti-
inflammatory drugs; SDMA: symmetric dimethylarginine.
vasculature and inflammation could promote vascular chan-
ges conducive to increased CV risk. Thus, it is not surprising
thatmorphologicalmarkers of atherosclerosis such as intima-
media thickness have been correlated with the magnitude
of systemic inflammation assessed by higher CRP values
[23] and patients with elevated ESR are at increased risk
of CV death compared to those with normal levels [24].
However, recent insights argue against a direct impact of
the inflammatory process on vascular wall, demonstrating
that systemic markers of inflammation do not correlate with
changes in noninvasive vascular assessments of microvas-
cular and macrovascular endothelial function characterizing
different stages of atherosclerosis [4].
On the other hand, reports on the association between
soluble biomarkers of endothelial dysfunction and indices
of systemic inflammation have provided inconsistent results
[25, 26]. Particularly for the dimethylarginines, conflicting
associations between ADMA and the acute phase response
have been reported, with some studies establishing positive
correlations with CRP and ESR [17, 27] and others yielding
negative results [28, 29].These discrepancies can be attributed
to differentmethodological approaches, cross-sectional study
designs, inclusion of small and heterogeneous patient pop-
ulations, and variations in disease duration, activity, and
treatment. Importantly, the method of characterising the
effect of inflammation on the vasculature may also influence
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Table 2: Univariable analysis of continuous factors.
SDMA
Coefficient (95% CI) 𝑝 value
BMI −0.5% (−1.1%, 0.0%) 0.063
HR −0.1% (−0.3%, 0.1%) 0.380
SBP 0.0% (−0.1%, 0.2%) 0.653
DBP 0.1% (−0.2%, 0.3%) 0.633
Log2 Reynolds Risk Score 1.5% (−0.8%, 3.9%) 0.191
Log2 Framingham Risk Score −0.1% (−3.2%, 3.2%) 0.955
eGFR −0.3% (−0.5%, 0.0%) 0.024∗
Log2 creatinine 12.0% (2.2%, 22.8%) 0.016
∗
Log2 AAUC CRP 0.2% (−3.4%, 3.9%) 0.916
Log2 AAUC ESR 2.0% (−1.0%, 5.0%) 0.192
Results from univariable regression models, with log2-transformed depen-
dent variables. Coefficients were then antilogged, to represent the percentage
change in the untransformed outcome for a unit increase in the factor.
For log2-transformed factors, the coefficient represents the increase in the
outcome for a twofold increase in the untransformed factor. ∗Significant at
𝑝 < 0.05. BMI: body mass index (kg/M2), HR: heart rate, SBP: systolic
blood pressure, DBP: diastolic blood pressure, eGFR: estimated glomerular
filtration rate, CRP: C-reactive protein, and ESR: estimated sedimentation
rate.
the findings of studies. For example, the magnitude and
chronicity of inflammation assessed with historical measures
of cumulative inflammatory burden probably represents a
more reliable marker of the total inflammatory burden to
which an RA individual has been exposed during the course
of the disease than a single reading of CRP or ESR [15]. To
lend more support to this, cumulative inflammation shows
better associations with noninvasive assessments of periph-
eral vascular function and morphology when compared
with current inflammatory levels [5]; however, only a small
number of studies have employed such an approach. Positive
correlations between cumulative inflammatory burden and
arterial stiffness have been reported in RA [30] and we
recently found similar associations for ADMA [17].
Despite previous observations, we did not demonstrate
any correlation between SDMA and cumulative inflam-
matory burden. One reason may be the effective control
of inflammatory disease in our cohort. Other potential
explanations include differences in biology between ADMA
and SDMA. It also appears that dimethylarginines may
promote endothelial dysfunction through different mech-
anisms even beyond NO synthase inhibition [31]. ADMA
mediates oxidative stress in vasculature through endothelial
NO synthase uncoupling and vice versa. Inflammation influ-
ences its metabolic pathways, resulting in elevated levels of
ADMA, predominantly due to dimethylarginine dimethy-
laminohydrolase inhibition [32]. Inflammation and oxidative
pathways represent important mechanisms accounting for
the pathogenetic role of ADMA in CV disease. However,
there has been limited understanding regarding the interplay
between SDMA and inflammation. It is worth noting that
SDMA remained unchanged in patients with acute bacterial
infection during the course of the disease whilst changes in
ADMA levels were noticed during the recovery phase of the
infection [33].
Table 3: Univariable analysis of categorical factors.
𝑁
SDMA
Average 𝑝 value
High cholesterol 0.275
No 122 0.45 (0.44–0.47)
Yes 64 0.47 (0.44–0.50)
Hypertension 0.866
No 69 0.46 (0.44–0.48)
Yes 117 0.46 (0.44–0.47)
Insulin resistance 0.149
No 136 0.46 (0.45–0.48)
Yes 50 0.44 (0.42–0.47)
Smoking 0.957
Never 84 0.46 (0.44–0.48)
Previously 78 0.45 (0.43–0.48)
Currently 22 0.46 (0.42–0.50)
Family history of cardiac events 0.506
No 102 0.46 (0.44–0.48)
Yes 84 0.45 (0.43–0.47)
MTX 0.837
No 69 0.46 (0.43–0.48)
Yes 117 0.46 (0.44–0.48)
Steroids 0.239
No 140 0.45 (0.44–0.47)
Yes 46 0.47 (0.44–0.51)
Anti-TNF 0.599
No 133 0.46 (0.44–0.47)
Yes 53 0.46 (0.44–0.49)
Antihypertensive 0.463
No 116 0.45 (0.44–0.47)
Yes 70 0.47 (0.44–0.49)
Data reported as “geometric mean (95% confidence interval)”, with 𝑝 values
from independent samples 𝑡-tests/one-way ANOVA on log2-transformed
values. Significant at 𝑝 < 0.05.
SDMA has been associated with the expression of proin-
flammatory cytokines in patients with chronic kidney dis-
ease [14], but the aetiology of chronic inflammatory status
characterising the uremic conditions differs from that of
high-grade systemic inflammatory diseases such as RA.
SDMA may exhibit proinflammatory properties associated
with abnormal renal function contributing to the moderate
inflammation present in the majority of uremic patients
and corroborating the previously demonstrated increase in
monocyte-mediated reactive oxygen species production [13].
However, the lack of association with inflammation in other
populations may indicate its main biologic role as a uremic
toxin and marker of renal function. In that respect, our
results confirm the presence of a relationship between serum
creatinine and SDMA in keeping with the findings from a
meta-analysis by Kielstein et al. [34].
Traditional CV risk factors aremore prevalent and poorly
controlled in RA compared to general population, but they
only partially account for the development of atherosclerosis
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and increasedCV risk [35]. It has been hypothesized that such
risk factors operate differently in RA and general population,
as some studies have reported that systemic inflammation
provides positive modulation to the effects of the established
factors in the vasculature and CV disease [36]. To lend more
support, the appreciation that risk algorithms used for CV
risk stratification in the general population underestimate the
risk of future events in RA patients underlines the complexity
of interrelations between traditional and disease-related risk
factors in this condition [37]. Metabolic alterations such as
insulin resistance, obesity, and aberrant lipid metabolism
are more frequent in patients with RA and are associated
with increased disease activity [38]. The association between
cardiometabolic syndrome and RA may be reciprocal, with
chronic low-grade inflammation characterising insulin resis-
tance and high-grade RA-related systemic inflammatory
activity reinforcing each other, resulting in a vicious circle
promoting oxidative stress and vascular damage. In our
cohort, CV risk factors were not found to influence SDMA
levels and, to the best of our knowledge, this is the first
study to investigate such associations, not only in RA, but
also in other high-risk patient populations. Similar results
have also been reported for ADMA in patients with RA
[17], coronary artery [39], and cerebrovascular disease [40].
Whether SDMA represents a surrogate marker of endothelial
dysfunction in RA remains to be determined. However, the
lack of associationwith cumulative inflammatory burden and
classic CV factors may suggest that, apart from a reliable
indicator of renal function, its utility as mediator of vascular
injury in RA may be limited.
Although the last decades have witnessed significant
advances in treatment of RA, the mortality gap between
RA individuals and general population has been widening,
mainly due to CV disease [41]. Subsequently, CV risk pre-
vention should constitute a key goal in management of this
condition [42]. Besides clinical recommendations [43], there
is an urgent need in identifying biomarkers to allow the
early recognition of RA patients at increased risk for CV
events and to facilitate individualised treatment strategies.
Dimethylarginines have been shown to predict CV mortality
and morbidity in the general [7, 44] population, but it is
questionable whether these observations are applicable to
RA where the pathogenesis of vascular damage may arise
through differentmechanisms triggered by inflammation and
immune activation. It is, therefore, unlikely that a single
biomarker could encompass the various processes involved
in endothelial dysfunction in RA. However, disruption of NO
metabolism is crucial, with ADMA and SDMA mediating,
probably through different pathways, the deleterious effects
of inflammation on the vascularwall andpromoting endothe-
lial injury and atherosclerosis. Such a process may be more
pronounced in chronic high-grade inflammatory conditions
such as RA, suggesting an important role for these molecules,
whose potential to predict future CV events in RA patients
remains to be investigated in large prospective studies with
hard CV disease end points.
Our study has several strengths, as we investigated the
association between SDMA and cumulative inflammation
in a large real-life RA population with sufficient assessment
and measurement of classical CV risk factors at baseline.
Furthermore, repeated measurement of inflammatory mark-
ers made it possible to take variability in disease activity
into account. In contrast, low disease activity in our patients
may have contributed to the negative results. The absence
of serial measurements of SDMA is another limitation, but
we are not aware of any data suggesting fluctuation of
SDMA levels over time. In addition, we excluded outliers
with extremely high SDMA from the analysis to ensure
the validity of our models. Finally, we did not find any
associations between SDMA and antirheumatic treatment.
However, large longitudinal studies with serialmeasurements
of ADMA and/or SDMA are warranted to address the ability
of dimethylarginines as indicators of potential endothelial
function improvement following treatment with synthetic
and biologic disease modifying drugs. Until today, only a
small study showed reduction in ADMA levels achieved with
biologic drugs [45] whilst others failed to demonstrate any
changes in concentrations of ADMA and SDMA in RA and
ankylosing spondylitis [46, 47].
4. Conclusion
In summary, our findings suggest that SDMA is independent
of cumulative inflammatory load assessed by quarterly mea-
surement of CRP and ESR for each year, as well as established
CV risk factors in RA, but associations between SDMA and
proinflammatory cytokines cannot be categorically excluded.
Altered NO homeostasis is considered an important mecha-
nism for vascular changes in RA and previous observations
have revealed that reduced NO availability is associated with
inflammation. However, the specific role of SDMA in the
development of atherosclerosis and abnormal endothelial
function in this population warrants further investigations.
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